Background: Hypertension is considered the most important risk factor for cardiovascular diseases, but its control is poor worldwide. We aimed to assess the availability and affordability of blood pressure-lowering medicines, and the association with use of these medici... View more
1 Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016; 388: 2665-712.
2 Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Chow KC, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959-68.
Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.
James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20.
WHO. The selection of essential drugs. 1977. http://apps.who.int/ medicinedocs/documents/s20185en/s20185en.pdf (accessed Sept 20, 2016).
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-12.
Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005; 42: 17-25.